Clinical trials: Carcinomas
Lung Cancer (NSCLC)
Surgical Outcome Of da Vinci Single-port Surgical System In Lung Cancer
Early-stage lung cancer represents a clinical challenge that, when diagnosed promptly, offers high chances of cure through lobectomy and lymphadenectomy.
- Trial name
- NCT07790406
- Testing
- da Vinci Single Port
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- European Institute of Oncology
Hepatocellular Carcinoma
Chemoembolization for Hepatocellular Carcinoma
The aim of the current study is to study the safety and effectiveness of TACE using a high dose of cisplatin for treatment of HCC.
- Trial name
- NCT02821533
- Testing
- TACE, Cisplatin
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer, Adenocarcinoma
Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer
To evaluate the role of biparametric MRI and image-fusion targeted biopsies for the detection of prostate cancer. To determine whether biparametric MRI (bpMRI) could be recommended as an alternative to multiparametric MRI (mpMRI)…
- Conditions
- Prostate Cancer, Adenocarcinoma, Prostatic Neoplasms, Prostatic Diseases
- Trial name
- IP7-PACIFIC (NCT05574647)
- Testing
- bpMRI, Image-Fusion targeted and systematic Biopsy
- Where
- 15 sites in United Kingdom
- Volunteers
- 3,600 people
- Sponsor
- Imperial College London
Carcinoma, Non-Small-Cell Lung
Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant…
- Trial name
- Cybertaxcis II (NCT06627738)
- Testing
- Cyberknife irradiation
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Antoine Lacassagne
Billiary Track Cancer
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab…
- Trial name
- NCT06001658
- Testing
- Gemcitabine, Cisplatin, Pembrolizumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy
- Trial name
- NCT04996758
- Testing
- Toripalimab and Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who…
- Conditions
- Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
- Trial name
- HCV-aMAP (NCT07687758)
- Testing
- Non-invasive Risk Score Assessment
- Where
- Thailand
- Volunteers
- 571 people
- Sponsor
- Siriraj Hospital
Squamous Cell Carcinoma, Oropharynx Cancer
PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
This proposal explores the novel hypothesis that the variability in outcomes within the Intermediate Risk(IR) HPV-positive Oropharynx Squamous Cell Carcinoma(OPSCC) cohort can be exploited to identify a subpopulation that…
- Trial name
- NCT03342378
- Testing
- Intensity modulated radiotherapy (IMRT), PET-MRI
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Wisconsin, Madison
Thyroid Cancer, Papillary, Leptin Levels
Leptin Levels in Papillary Thyroid Cancer
The purpose of this study is to evaluate Leptin levels in females, in the setting of papillary thyroid cancer, benign thyroid nodules, and in normal females without thyroid disease.
- Trial name
- LL-PTC (NCT01659385)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, cisplatin, paclitaxel, and vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072215
- Testing
- cisplatin, ifosfamide, paclitaxel
- Where
- 79 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Endometrial Cancer
END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin
The purpose of this study is to evaluate activity and toxicity of the combination of carboplatin and liposomal doxorubicin as first-line chemotherapy of patients with advanced or recurrent endometrial carcinoma.
- Trial name
- NCT00401635
- Testing
- liposomal doxorubicin, carboplatin
- Where
- 4 sites in Italy
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute, Naples
Locally Advanced/Metastatic/Recurrent ESCC
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line…
- Trial name
- NCT07417735
- Testing
- SYS6010, Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel)
- Volunteers
- 436 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Hepatocellular Carcinoma (HCC)
Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma
Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC). The aim of the single-arm, open-label, phase II clinical trial is to evaluate the efficacy and safety of lenvatinib as an adjuvant…
- Trial name
- NCT04227808
- Testing
- Lenvima 4 mg Oral Capsule
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Transitional Cell Carcinoma
A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy
An open-label, single arm, non-randomized, single stage phase II study. 3 phases:Baseline, treatment/duration and Follow-up. All patients will be treated with RAD001 10 mg daily dose until disease progression or unacceptable…
- Trial name
- NCT00714025
- Testing
- RAD001
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
This study aims to evaluate the efficacy and safety of DS-1062a in participants with metastatic, unresectable NSCLC having progressed on one, but not more than three previous standard therapies.
- Conditions
- Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer
- Trial name
- ICARUS-LUNG01 (NCT04940325)
- Testing
- DS-1062a
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Infiltrating Bladder Urothelial Carcinoma
A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer
If radical cystectomy remains the standard of care for muscle invasive bladder cancer, consequences of this surgical procedure are often harsh.
- Trial name
- GETUGV04 (NCT01495676)
- Testing
- Radiation + cisplatin, Radiation + cisplatin + gemcitabine
- Where
- 12 sites in France
- Volunteers
- 69 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Non-small Cell Lung Cancer
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery.
- Trial name
- INTerpath-014 (NCT07513376)
- Testing
- Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa
- Where
- 124 sites in United States, Australia and 18 more
- Volunteers
- 876 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Gold sodium thiomalate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of gold sodium thiomalate in…
- Trial name
- NCT00575393
- Testing
- gold sodium thiomalate, gene expression analysis, fluorine F 18 fluorothymidine
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Small Cell Lung Cancer
Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
The scope of the PICASSO project is to apply an innovative patient-based pan-omic approach to immune-assays, that will include multi-omics tumour characterization (genome, proteome, transcriptome), blood immune-cells and cytokine…
- Trial name
- PICASSO (NCT05797493)
- Testing
- Atezolizumab
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Esophageal Neoplasms
Safety Study on the Transfer of the CD40 Ligand Gene (AdcuCD40L) to Patients With Esophageal Carcinoma
This a pilot clinical study focused on enhancing the patient's anti-tumor immune response in individuals with esophageal cancer by altering the genetic repertoire of the tumors to express CD40L, an activator of dendritic cells.
- Trial name
- NCT00328887
- Testing
- CD40 Gene Transfer
- Where
- 2 sites in United States
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.